Sodium benzoate is under clinical development by SyneuRx International (Taiwan) and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sodium benzoate’s likelihood of approval (LoA) and phase transition for Schizophrenia took place on 20 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sodium benzoate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sodium benzoate overview

Sodium benzoate (SND-1, SB-01, SR-01) is under development for the treatment of adolescent schizophrenia, refractory schizophrenia, add-on therapy in schizophrenia and dementia.  It is administered through the oral route. It acts by targeting D-amino acid oxidase (DAAO).

SyneuRx International (Taiwan) overview

SyneuRx International (Taiwan) (SyneuRx International) is a bio-medical company that specializes in developing drugs for the treatment of central nervous system-related disorders. The company is headquartered in Taipei City, Taipei, Taiwan.

Quick View Sodium benzoate LOA Data

Report Segments
  • Innovator
Drug Name
  • Sodium benzoate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: SyneuRx International (Taiwan)
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.